uniQure N.V. (QURE), Thursday said U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntingtons disease, a rare, inherited neurodegenerative disorder.
Breakthrough Therapy designation is a process to expedite the development and review of drugs that are intended to treat serious conditions where early clinical evidence indicates a substantial improvement over existing therapies.
The gene therapy candidate has already been granted Regenerative Medicine Advanced Therapy (RMAT) designation, Orphan Drug designation and Fast Track designation.
The Breakthrough Therapy designation is supported by data from the ongoing Phase I/II studies of AMT-130 for the treatment of Huntingtons disease. In July 2024, uniQure presented interim data at 24 months that showed dose-dependent slowing of disease progression in patients treated with AMT-130.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.